

Peter R Galle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1578158/publications.pdf>

Version: 2024-02-01

583
papers

57,972
citations

3933

88
h-index

1284

225
g-index

597
all docs

597
docs citations

597
times ranked

46368
citing authors

#	ARTICLE	IF	CITATIONS
1	NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. <i>Journal of Hepatology</i> , 2022, 76, 446-457.	3.7	121
2	Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). <i>Clinical and Translational Science</i> , 2022, 15, 141-157.	3.1	13
3	Burden of depression and anxiety disorders per disease codes in patients with lymphoma in Germany. <i>Supportive Care in Cancer</i> , 2022, 30, 2387-2395.	2.2	1
4	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	3.7	1,495
5	Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis. <i>European Journal of Internal Medicine</i> , 2022, 98, 53-60.	2.2	4
6	Six-Month Follow-Up after Vaccination with BNT162b2: SARS-CoV-2 Antigen-Specific Cellular and Humoral Immune Responses in Hemodialysis Patients and Kidney Transplant Recipients. <i>Pathogens</i> , 2022, 11, 67.	2.8	13
7	ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS498-TPS498.	1.6	7
8	Ramucirumab for patients with advanced hepatocellular carcinoma and elevated α -fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2.. <i>Journal of Clinical Oncology</i> , 2022, 40, 423-423.	1.6	3
9	Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. <i>JHEP Reports</i> , 2022, 4, 100417.	4.9	6
10	Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>United European Gastroenterology Journal</i> , 2022, 10, 41-53.	3.8	12
11	Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 862-873.	3.7	568
12	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
13	Emerging immunotherapy for HCC: A guide for hepatologists. <i>Hepatology</i> , 2022, 75, 1604-1626.	7.3	97
14	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2567-2576.e6.	4.4	80
15	Sonographic assessment of low muscle quantity identifies mortality risk during COVID-19: a prospective single-centre study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 169-179.	7.3	9
16	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2297-2305.	7.0	8
17	Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver Cirrhosis. <i>Diagnostics</i> , 2022, 12, 1069.	2.6	5
18	Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL. <i>Journal of Hepatology</i> , 2022, 77, 695-701.	3.7	30

#	ARTICLE	IF	CITATIONS
19	Influence of Advanced Organ Support (ADVOS) on Cytokine Levels in Patients with Acute-on-Chronic Liver Failure (ACLF). <i>Journal of Clinical Medicine</i> , 2022, 11, 2782.	2.4	4
20	N-Cadherin Distinguishes Intrahepatic Cholangiocarcinoma from Liver Metastases of Ductal Adenocarcinoma of the Pancreas. <i>Cancers</i> , 2022, 14, 3091.	3.7	3
21	Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver Disease in Germany. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3179-3185.	2.3	32
22	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	7.3	235
23	Local and Regional Therapies for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 137-149.	7.3	69
24	Possible misclassification of cardiovascular risk by SCORE in antisynthetase syndrome: results of the pilot multicenter study RI.CAR.D.A. <i>Rheumatology</i> , 2021, 60, 1300-1312.	1.9	8
25	Systemic treatment of HCC in special populations. <i>Journal of Hepatology</i> , 2021, 74, 931-943.	3.7	72
26	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021, 41, 598-607.	3.9	13
27	High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2021, 9, 388-397.	3.8	4
28	Systemic therapy of advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2021, 17, 1237-1251.	2.4	31
29	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	4.9	31
30	A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS349-TPS349.	1.6	10
31	Evaluation of a novel colonoscope offering flexibility adjuster " a retrospective observational study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110134.	3.2	0
32	Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 323-323.	1.6	4
33	IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 267-267.	1.6	226
34	Functional inhibition of Oct leads to HNF4 α upregulation. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 349.	1.8	0
35	Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, , .	1.2	6
36	No Evidence for Classic Thrombotic Microangiopathy in COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 671.	2.4	9

#	ARTICLE	IF	CITATIONS
37	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. <i>British Journal of Cancer</i> , 2021, 124, 1388-1397.	6.4	39
38	Dr. Triantafyllias, et al reply. <i>Journal of Rheumatology</i> , 2021, 48, 951-951.	2.0	1
39	COVID-19â€™Importance for Patients on the Waiting List and after Kidney Transplantationâ€™A Single Center Evaluation in 2020â€™2021. <i>Pathogens</i> , 2021, 10, 429.	2.8	3
40	The Current Landscape of Clinical Trials for Systemic Treatment of HCC. <i>Cancers</i> , 2021, 13, 1962.	3.7	40
41	Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay for non-COVID-19 patient screening at hospital admission. <i>Medical Microbiology and Immunology</i> , 2021, 210, 165-171.	4.8	20
42	The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. <i>Cancers</i> , 2021, 13, 2296.	3.7	47
43	Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α -fetoprotein: Outcomes by treatmentâ€™emergent ascites. <i>Hepatology Research</i> , 2021, 51, 715-721.	3.4	5
44	IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4071-4071.	1.6	21
45	The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0249426.	2.5	11
46	Health-related quality of life in patients with autoimmune hepatitis. <i>Quality of Life Research</i> , 2021, 30, 2853-2861.	3.1	5
47	Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?. <i>Frontiers in Oncology</i> , 2021, 11, 696183.	2.8	17
48	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. <i>Liver International</i> , 2021, 41, 2759-2767.	3.9	5
49	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
50	Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. <i>United European Gastroenterology Journal</i> , 2021, 9, 590-597.	3.8	9
51	The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2732.	2.4	8
52	Risk factors for poorer health literacy in patients with liver cirrhosis. <i>PLoS ONE</i> , 2021, 16, e0255349.	2.5	14
53	COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report. <i>Hamostaseologie</i> , 2021, , .	1.9	2
54	Impact of thyroid disorders on the incidence of nonâ€™alcoholic fatty liver disease in Germany. <i>United European Gastroenterology Journal</i> , 2021, 9, 829-836.	3.8	9

#	ARTICLE	IF	CITATIONS
55	Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2335-2347.	3.8	27
56	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 991-1001.	10.7	179
57	Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B. <i>BMC Health Services Research</i> , 2021, 21, 846.	2.2	2
58	Evaluation of novel LCI CAD EYE system for real time detection of colon polyps. <i>PLoS ONE</i> , 2021, 16, e0255955.	2.5	18
59	Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. <i>Cancers</i> , 2021, 13, 3961.	3.7	7
60	Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis. <i>JCI Insight</i> , 2021, 6, .	5.0	9
61	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
62	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , 2021, 75, 960-974.	3.7	217
63	Decision making in systemic therapy of hepatocellular carcinoma: Should we pay attention to disease aetiology?. <i>Journal of Hepatology</i> , 2021, 75, 763-764.	3.7	1
64	Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension – case-report-based discussion. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, 43-49.	0.5	5
65	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). <i>Liver Cancer</i> , 2021, 10, 451-460.	7.7	5
66	Liver injury in patients with severe acute respiratory syndrome coronavirus-2 infection: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1194-1200.	1.6	15
67	Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis. <i>Scientific Reports</i> , 2021, 11, 20506.	3.3	4
68	Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. <i>Cancers</i> , 2021, 13, 5018.	3.7	16
69	Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.. <i>Journal of Hepatology</i> , 2021, , .	3.7	3
70	Association Between Serum Levels of Neurofilament Light Chains and Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00419.	2.5	5
71	Portal Vein Thrombosis Is Associated with an Increased Incidence of Depression and Anxiety Disorders. <i>Journal of Clinical Medicine</i> , 2021, 10, 5689.	2.4	1
72	Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2112-2119.	2.3	68

#	ARTICLE	IF	CITATIONS
73	Sarcopenia as prognostic factor for survival after orthotopic liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 626-634.	1.6	28
74	Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC). <i>Digestive Diseases and Sciences</i> , 2020, 65, 3006-3013.	2.3	14
75	Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: A case report. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2990-2994.	0.5	5
76	Impact of non-selective β -blockers on hepatic encephalopathy in patients with liver cirrhosis. <i>European Journal of Internal Medicine</i> , 2020, 82, 83-89.	2.2	2
77	Validation of the Clinical Frailty Scale for the Prediction of Mortality in Patients With Liver Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00211.	2.5	15
78	Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 942-948.	3.8	43
79	Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	4
80	Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1042-1050.	3.7	7
81	Distant Metastases in Patients with Intrahepatic Cholangiocarcinoma: Does Location Matter? A Retrospective Analysis of 370 Patients. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	11
82	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). <i>Oncolmmunology</i> , 2020, 9, 1806680.	4.6	11
83	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. <i>ESMO Open</i> , 2020, 5, e000797.	4.5	18
84	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2495.	3.7	12
85	Proton pump inhibitor use is associated with a variety of infections in patients with liver cirrhosis. <i>Medicine (United States)</i> , 2020, 99, e23436.	1.0	10
86	Role of Immunotherapy in the Management of Hepatocellular Carcinoma: Current Standards and Future Directions. <i>Current Oncology</i> , 2020, 27, 152-164.	2.2	14
87	Investigating the impact of extrahepatic metastasis in patients with HCC: does location matter?. <i>Journal of Hepatology</i> , 2020, 73, S370-S371.	3.7	0
88	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy – Achieving global consensus and visibility for cellular host-directed therapies. <i>International Journal of Infectious Diseases</i> , 2020, 96, 431-439.	3.3	43
89	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 382, 1894-1905.	27.0	3,828
90	Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. <i>Hepatology Communications</i> , 2020, 4, 1293-1301.	4.3	70

#	ARTICLE	IF	CITATIONS
91	BAX Redistribution Induces Apoptosis Resistance and Selective Stress Sensitivity in Human HCC. <i>Cancers</i> , 2020, 12, 1437.	3.7	11
92	Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1883-1890.	2.5	9
93	Patterns of liver injury in COVID-19 – a German case series. <i>United European Gastroenterology Journal</i> , 2020, 8, 814-819.	3.8	23
94	Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 527-536.	3.7	29
95	Clinical Frailty Scale for Risk Stratification in Patients with Sars-Cov-2 Infection. <i>Journal of Investigative Medicine</i> , 2020, 68, 1199-1202.	1.6	32
96	Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. <i>United European Gastroenterology Journal</i> , 2020, 8, 444-452.	3.8	9
97	In vitro prediction of in vivo absorption of ibuprofen from suspensions through rational choice of dissolution conditions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 149, 229-237.	4.3	14
98	Urinary ethyl glucuronide (uEtG) as a marker for alcohol consumption in liver transplant candidates: a real-world cohort. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 30-38.	0.5	3
99	A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 57-62.	0.5	5
100	Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 10.	2.4	7
101	Management of hepatic encephalopathy in Germany: a survey among physicians. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 49-56.	0.5	15
102	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	3.7	165
103	Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study. <i>Liver International</i> , 2020, 40, 694-703.	3.9	32
104	Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8th edition of the UICC/AJCC Cancer staging system. <i>PLoS ONE</i> , 2020, 15, e0228501.	2.5	5
105	Diagnostic Value of Optical Spectral Transmission in Rheumatoid Arthritis: Associations with Clinical Characteristics and Comparison with Joint Ultrasonography. <i>Journal of Rheumatology</i> , 2020, 47, 1314-1322.	2.0	8
106	Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1754-1759.	6.4	17
107	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	3.9	26
108	Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 476-476.	1.6	28

#	ARTICLE	IF	CITATIONS
109	Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 15-24.	0.9	5
110	Cholelithiasis in Patients with Gaucher Disease type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 447-455.	0.9	7
111	Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease. <i>Deutsches A&#x0308;rzteblatt International</i> , 2020, 117, 719-724.	0.9	21
112	Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 423-433.	3.7	4
113	Molecular endoscopic imaging for the detection of Barrett's metaplasia using biodegradable inorganic nanoparticles: An ex-vivo pilot study on human tissue. <i>PLoS ONE</i> , 2020, 15, e0239814.	2.5	2
114	Pilot Study on Malnutrition and DNA Damage in Patients with Newly Diagnosed Gastrointestinal Tumors: Is DNA Damage Reversible by Early Individualized Nutritional Support?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 569-577.	0.9	0
115	Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 2214-2229.	3.9	327
116	Tu1967 MOLECULAR ENDOSCOPIC IMAGING FOR TARGETED VISUALIZATION OF CELL ADHESION MOLECULES IN PATIENTS WITH LIVER CIRRHOSIS. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB634-AB635.	1.0	0
117	Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFβ2. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G195-G202.	3.4	11
118	Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. <i>United European Gastroenterology Journal</i> , 2019, 7, 838-849.	3.8	23
119	Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 930-939.	3.7	67
120	Tu1141 EVALUATION OF A NEW DEMILUNE SHAPED DEVICE FOR ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD). <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB576.	1.0	0
121	Comparison of the current international guidelines on the management of HCC. <i>JHEP Reports</i> , 2019, 1, 114-119.	4.9	30
122	FRI-208-Predictors of treatment response during addition of pegylated Interferon alfa-2a to an ongoing nucleos (t)id treatment in chronic hepatitis B: Results from the PADD-ON trial. <i>Journal of Hepatology</i> , 2019, 70, e485.	3.7	0
123	Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. <i>Hepatology Communications</i> , 2019, 3, 1472-1481.	4.3	26
124	Mo1334 DIAGNOSTIC YIELD OF ENDOSCOPY FOR PREDICTION OF ACUTE GRAFT VERSUS HOST DISEASE IN THE UPPER GASTROINTESTINAL TRACT. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB496.	1.0	0
125	Su1710 PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF TWO DIFFERENT WIRE TECHNIQUES FOR COLD SNARE POLYPECTOMY. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB389.	1.0	0
126	Su1348 ROLE OF THE NOVEL INTRODUCED PAN-INTESTINAL CAPSULE ENDOSCOPY SYSTEM IN CELIAC DISEASE. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB340.	1.0	0

#	ARTICLE	IF	CITATIONS
127	Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1112-1119.	3.7	28
128	SAT-069-Interleukin 6: A marker for hepatic encephalopathy. <i>Journal of Hepatology</i> , 2019, 70, e657.	3.7	0
129	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019, 71, 1141-1151.	3.7	104
130	GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH). <i>Journal of Hepatology</i> , 2019, 70, e46.	3.7	6
131	Molecular endoscopic imaging: the future is bright. <i>Therapeutic Advances in Gastrointestinal Endoscopy</i> , 2019, 12, 263177451986717.	1.9	5
132	SAT-067-Prospective assessment of sarcopenia as a prognostic factor for survival in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e656-e657.	3.7	0
133	THU-453-Dissecting the landscape of (epi-)genetic alterations during sequential evolution of liver cancer. <i>Journal of Hepatology</i> , 2019, 70, e358-e359.	3.7	4
134	Mo1702 DEVELOPMENT OF A NEW CLASSIFICATION SYSTEM FOR ASSESSMENT OF MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE (IBD) USING NARROW BAND IMAGING (NBI). <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB527-AB528.	1.0	0
135	Health-related quality of life in patients with compensated and decompensated liver cirrhosis. <i>European Journal of Internal Medicine</i> , 2019, 70, 54-59.	2.2	35
136	A novel technique for intraduodenal administration of drug suspensions/solutions with concurrent pH monitoring applied to ibuprofen formulations. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 136, 192-202.	4.3	8
137	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 282-296.	10.7	1,202
138	Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-12.	1.9	4
139	The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?. <i>Liver International</i> , 2019, 39, 1307-1314.	3.9	20
140	Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e303-e307.	2.2	17
141	Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters – an animal model of life style intervention in NAFLD. <i>Scientific Reports</i> , 2019, 9, 4007.	3.3	31
142	Expression and prognostic significance of insulin-like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization. <i>Oncology Reports</i> , 2019, 41, 2299-2310.	2.6	5
143	Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. <i>United European Gastroenterology Journal</i> , 2019, 7, 529-537.	3.8	16
144	Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α -fetoprotein. <i>Lancet Oncology</i> , The, 2019, 20, e191.	10.7	42

#	ARTICLE	IF	CITATIONS
145	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2085-2092.e1.	4.4	79
146	FRIO628â€¦DIAGNOSTIC VALUE OF OPTICAL SPECTRAL TRANSMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS: CORRELATIONS WITH DISEASE ACTIVITY, EPIDEMIOLOGIC AND ANTHROPOMETRIC PARAMETERS. , 2019, , .		0
147	AB0691â€¦INCREASED CARDIOVASCULAR RISK IN MIXED CONNECTIVE TISSUE DISEASE: EVALUATION OF MACROVASCULAR INVOLVEMENT AND ITS PREDICTORS BY AORTIC PULSE WAVE VELOCITY. , 2019, , .		2
148	Su1709 DIAGNOSTIC ABILITY OF BLUE LIGHT IMAGING FOR PREDICTING DEEP SUBMUCOSAL INVASION IN COLORECTAL LESIONS. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB388-AB389.	1.0	0
149	Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2019, 114, 764-770.	0.4	27
150	Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2019, 270, 799-805.	4.2	54
151	Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy. <i>European Journal of Internal Medicine</i> , 2019, 60, 96-100.	2.2	24
152	Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 387-402.	7.7	18
153	Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naïve patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. <i>BMC Cancer</i> , 2019, 19, 55.	2.6	24
154	Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGF β Signaling and Promote Colitis. <i>Gastroenterology</i> , 2019, 156, 692-707.e7.	1.3	24
155	Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?. <i>Liver International</i> , 2019, 39, 324-331.	3.9	55
156	Application of patientâ€¦derived liver cancer cells for phenotypic characterization and therapeutic target identification. <i>International Journal of Cancer</i> , 2019, 144, 2782-2794.	5.1	19
157	Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH,) Tj ETQq1 1 0.784314 rgBT /Ove		
158	A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4103-4103.	1.6	38
159	Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4152-TPS4152.	1.6	94
160	Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α -fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 326-326.	1.6	8
161	Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantation. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 53-61.	0.9	2
162	High cardiovascular risk in mixed connective tissue disease: evaluation of macrovascular involvement and its predictors by aortic pulse wave velocity. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 994-1002.	0.8	3

#	ARTICLE	IF	CITATIONS
163	Patient prioritisation in HCC treatment: All (good) things come in threes. <i>Journal of Hepatology</i> , 2018, 68, 1311-1312.	3.7	3
164	The role of molecular enrichment on future therapies in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 237-247.	3.7	95
165	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	3.7	6,153
166	Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation. <i>Journal of Hepatology</i> , 2018, 68, 986-995.	3.7	106
167	The Manchester Triage System (MTS): a score for emergency management of patients with acute gastrointestinal bleeding. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 479-487.	0.5	3
168	Advanced endoscopic imaging for diagnosis of inflammatory bowel diseases: Present and future perspectives. <i>Digestive Endoscopy</i> , 2018, 30, 441-448.	2.3	12
169	Prediction of clinical outcomes in Crohn's disease by using confocal laser endomicroscopy: results from a prospective multicenter study. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 1505-1514.e3.	1.0	25
170	Two large steps forward, one small step back. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 74-76.	17.8	18
171	The immune contexture of hepatocellular carcinoma predicts clinical outcome. <i>Scientific Reports</i> , 2018, 8, 5351.	3.3	93
172	Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Digestive Diseases</i> , 2018, 36, 78-88.	1.9	7
173	Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G319-G333.	3.4	16
174	Hepatocellular carcinoma: one world, one cancer's different guidelines?. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 41-43.	1.5	4
175	Ginkgo biloba induces different gene expression signatures and oncogenic pathways in malignant and non-malignant cells of the liver. <i>PLoS ONE</i> , 2018, 13, e0209067.	2.5	13
176	Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: A real-world cohort. <i>Clinical Transplantation</i> , 2018, 32, e13411.	1.6	13
177	<i>Helicobacter pylori</i> Infection as a Risk Factor for Hepatocellular Carcinoma: A Case-Control Study in Ethiopia. <i>International Journal of Hepatology</i> , 2018, 2018, 1-7.	1.1	10
178	Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1109-1116.	3.7	88
179	Leaving colorectal polyps in place can be achieved with high accuracy using blue light imaging (BLI). <i>United European Gastroenterology Journal</i> , 2018, 6, 1099-1105.	3.8	19
180	Guidelines are silver, but a multidisciplinary team discussion may be golden?. <i>Liver International</i> , 2018, 38, 1550-1551.	3.9	0

#	ARTICLE	IF	CITATIONS
181	Feasibility Trial of the Newly Introduced Optical Enhancement Technology in Patients with Gastroesophageal Reflux Disease. <i>Digestive Diseases</i> , 2018, 36, 450-455.	1.9	0
182	Molecular endoscopic imaging in cancer. <i>Digestive Endoscopy</i> , 2018, 30, 719-729.	2.3	14
183	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , 2018, 68, 16-24.	7.7	124
184	Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort. <i>BMC Cancer</i> , 2018, 18, 774.	2.6	9
185	Ultrasound for Hepatocellular Carcinoma Surveillance: Still Looking for the Fortune Teller. <i>Liver Transplantation</i> , 2018, 24, 1167-1168.	2.4	1
186	Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 489.	2.6	16
187	Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. <i>Journal of Hepatology</i> , 2018, 69, 982-984.	3.7	22
188	Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function. <i>International Journal of Cardiology</i> , 2018, 271, 296-300.	1.7	23
189	Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study. <i>Transplant International</i> , 2018, 31, 1207-1215.	1.6	32
190	Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC. <i>European Journal of Internal Medicine</i> , 2018, 55, 57-65.	2.2	6
191	REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4003-4003.	1.6	77
192	IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4141-TPS4141.	1.6	38
193	A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4144-TPS4144.	1.6	73
194	A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS538-TPS538.	1.6	21
195	Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation. <i>Hepatology</i> , 2017, 65, 2074-2089.	7.3	7
196	Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1017-1025.	2.0	17
197	Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1023-1034.	2.5	2
198	Immune oncology in hepatocellular carcinoma—hype and hope. <i>Lancet, The</i> , 2017, 389, 2448-2449.	13.7	10

#	ARTICLE	IF	CITATIONS
199	Elevated levels of Bcl-3 inhibits Treg development and function resulting in spontaneous colitis. Nature Communications, 2017, 8, 15069.	12.8	22
200	Treating Hepatobiliary Cancers: The Oncology Way. Digestive Diseases, 2017, 35, 384-386.	1.9	8
201	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterology Journal, 2017, 5, 987-996.	3.8	49
202	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology, 2017, 67, 173-183.	3.7	165
203	Current progress in immunotherapy of hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 482-484.	3.7	53
204	Sa1104 Evaluation of a Novel Colonoscope Offering Flexibility Adjuster and a Multi-Led Technology. Gastrointestinal Endoscopy, 2017, 85, AB192-AB193.	1.0	0
205	Sa1759 Safety and Efficacy of the Fuse-System in Patients With Inflammatory Bowel Disease (IBD) and Infectious Colitis. Gastrointestinal Endoscopy, 2017, 85, AB269.	1.0	0
206	Su1661 Leaving Colorectal Polyps in Place Can Be Achieved With High Accuracy Using Blue Light Imaging (BLI). Gastrointestinal Endoscopy, 2017, 85, AB385.	1.0	0
207	Reply to: Performance status in patients with HCC: New kid on the block. Journal of Hepatology, 2017, 67, 1353-1355.	3.7	1
208	Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieu. Cell Death and Disease, 2017, 8, e2893-e2893.	6.3	13
209	Sorafenib in Patients with Hepatocellular Carcinoma—Results of the Observational INSIGHT Study. Clinical Cancer Research, 2017, 23, 5720-5728.	7.0	67
210	Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2017, 28, 94-102.	0.5	34
211	Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort. Drug Design, Development and Therapy, 2017, Volume 11, 2131-2138.	4.3	11
212	Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. Deutsches Arzteblatt International, 2017, 114, 597-602.	0.9	9
213	A phase 2 study of galunisertib (TGF- β 1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 2017, 35, 4097-4097.	1.6	5
214	Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF- κ B activation. Oncotarget, 2017, 8, 56095-56109.	1.8	9
215	Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas. Oncotarget, 2017, 8, 48688-48700.	1.8	15
216	Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis. Oncotarget, 2017, 8, 115667-115680.	1.8	16

#	ARTICLE	IF	CITATIONS
217	Efficacy of image enhanced endoscopy for colorectal polyps: Are we ready for prime time?. Saudi Journal of Gastroenterology, 2017, 23, 1.	1.1	0
218	Portal vein infiltration in patients with hepatocellular carcinoma: The relevance of correct classification.. Journal of Clinical Oncology, 2017, 35, e15651-e15651.	1.6	0
219	Abstract 1902: Enrichment of putative cancer stem cells during anti-angiogenic therapies promotes relapse formation in hepatocellular carcinoma. , 2017, , .		0
220	Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. European Journal of Gastroenterology and Hepatology, 2016, 28, 187-192.	1.6	7
221	Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World Journal of Gastroenterology, 2016, 22, 5400.	3.3	6
222	Viral Hepatitis and Its Complications: Management of Hepatocellular Carcinoma. Visceral Medicine, 2016, 32, 127-130.	1.3	1
223	Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer, 2016, 16, 699.	2.6	54
224	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clinical Gastroenterology and Hepatology, 2016, 14, 875-886.e6.	4.4	217
225	Extended Abstract: Management of Liver Cancer. Digestive Diseases, 2016, 34, 438-439.	1.9	7
226	Past, present and future of immunology in Mainz. Cellular Immunology, 2016, 308, 1-6.	3.0	0
227	Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. Visceral Medicine, 2016, 32, 110-115.	1.3	9
228	Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors. Journal of Hepatology, 2016, 65, 1188-1197.	3.7	16
229	Analysis of the expression of SDF-1 splicing variants in human colorectal cancer and normal mucosa tissues. Oncology Letters, 2016, 11, 1873-1878.	1.8	10
230	Functional diversity of stromal cell-derived factor 1 splice variants in colorectal cancer and melanoma. International Journal of Colorectal Disease, 2016, 31, 1225-1226.	2.2	0
231	EASL Recognition Award Recipient 2016: Prof. Jordi Bruix. Journal of Hepatology, 2016, 64, 998-1000.	3.7	0
232	Changes in lipid and carbohydrate metabolism under mTOR- and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation. European Journal of Internal Medicine, 2016, 29, 104-109.	2.2	24
233	Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer, 2016, 16, 94.	2.6	37
234	The 9th Annual Conference of the International Liver Cancer Association (ILCA) 2015. Hepatic Oncology, 2016, 3, 9-12.	4.2	0

#	ARTICLE	IF	CITATIONS
235	Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. <i>Digestive and Liver Disease</i> , 2016, 48, 291-297.	0.9	44
236	PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4146-TPS4146.	1.6	38
237	A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS478-TPS478.	1.6	2
238	The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0151200.	2.5	21
239	Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice. <i>Oncotarget</i> , 2016, 7, 28903-28913.	1.8	6
240	A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4145-TPS4145.	1.6	2
241	Dermatux: Phase IV trial of C-FOLFIRI in 1 st -line metastatic colorectal cancer receiving a pre-defined skin care.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15048-e15048.	1.6	0
242	Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15593-e15593.	1.6	0
243	Predictive Scores in Primary Biliary Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 438-447.	2.2	12
244	Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan [®] and Mowel [®] after liver transplantation. <i>Drug Design, Development and Therapy</i> , 2015, 9, 6139.	4.3	3
245	Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. <i>BMC Cancer</i> , 2015, 15, 210.	2.6	87
246	Survival analysis of proposed BCLC subgroups in hepatocellular carcinoma patients. <i>Liver International</i> , 2015, 35, 591-600.	3.9	60
247	Familial amyloidosis: Great progress for an orphan disease. <i>Journal of Hepatology</i> , 2015, 62, 483-485.	3.7	5
248	Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 515-522.	2.5	10
249	Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 352-360.	2.0	95
250	Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. <i>Journal of Hepatology</i> , 2015, 62, 863-870.	3.7	63
251	Curcumin effectively inhibits oncogenic NF- κ B signaling and restrains stemness features in liver cancer. <i>Journal of Hepatology</i> , 2015, 63, 661-669.	3.7	237
252	Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center real-life-cohort. <i>BMC Gastroenterology</i> , 2015, 15, 97.	2.0	19

#	ARTICLE	IF	CITATIONS
253	Translating bioinformatics in oncology: guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis. <i>Bioinformatics</i> , 2015, 31, 216-224.	4.1	63
254	Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. <i>Liver International</i> , 2015, 35, 176-183.	3.9	4
255	Intraprocedural bowel cleansing with the JetPrep cleansing system improves adenoma detection. <i>World Journal of Gastroenterology</i> , 2015, 21, 8184.	3.3	9
256	Triple antiviral therapy with telaprevir after liver transplantation: a case series. <i>Transplant Research and Risk Management</i> , 2014, , 73.	0.7	2
257	Disclosure and Experienced Social Support are not Related to Anxiety or Depression in a German HIV Patient Cohort. <i>Infection and Chemotherapy</i> , 2014, 46, 77.	2.3	8
258	Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 83.	8.6	13
259	Moguntinonesâ€”New Selective Inhibitors for the Treatment of Human Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1399-1409.	4.1	5
260	Immune Control in Hepatocellular Carcinoma Development and Progression: Role of Stromal Cells. <i>Seminars in Liver Disease</i> , 2014, 34, 376-388.	3.6	32
261	Sorafenib for the treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2014, 1, 189-204.	4.2	7
262	Overexpression of Bclâ€”3 inhibits the development of marginal zone B cells. <i>European Journal of Immunology</i> , 2014, 44, 545-552.	2.9	17
263	CellMiner<sc>HCC</sc>: a microarrayâ€”based expression database for hepatocellular carcinoma cell lines. <i>Liver International</i> , 2014, 34, 621-631.	3.9	15
264	Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 279-289.	2.2	80
265	Confocal Endomicroscopy Identifies Loss of Local Barrier Function in the Duodenum of Patients with Crohnâ€”s Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 892-900.	1.9	71
266	Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1. <i>Frontiers in Oncology</i> , 2014, 4, 92.	2.8	22
267	To Biopsy or Not to Biopsy: Evaluation of a Large German Cohort of Patients with Abnormal Liver Tests of Unknown Etiology. <i>Digestion</i> , 2014, 89, 310-318.	2.3	2
268	Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation. <i>Digestive and Liver Disease</i> , 2014, 46, 88-89.	0.9	18
269	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014, 60, 1268-1289.	3.7	1,151
270	Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. <i>International Journal of Clinical Oncology</i> , 2014, 19, 288-296.	2.2	11

#	ARTICLE	IF	CITATIONS
271	Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. <i>Journal of Hepatology</i> , 2014, 60, 346-353.	3.7	85
272	Treatment of Malignant Ascites with a Second Cycle of Catumaxomab in Gastric Signet Cell Carcinoma - a Report of 2 Cases. <i>Oncology Research and Treatment</i> , 2014, 37, 674-677.	1.2	5
273	HCC therapies—lessons learned. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 447-452.	17.8	128
274	High definition plus colonoscopy combined with i-scan tone enhancement vs. high definition colonoscopy for colorectal neoplasia: A randomized trial. <i>Digestive and Liver Disease</i> , 2014, 46, 991-996.	0.9	29
275	High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. <i>International Journal of Cancer</i> , 2014, 134, 1926-1934.	5.1	79
276	VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>BMC Cancer</i> , 2014, 14, 476.	2.6	8
277	Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 311.	1.6	24
278	Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia. <i>Nature Genetics</i> , 2014, 46, 901-904.	21.4	104
279	Acetic acid compared with i-scan imaging for detecting Barrett's esophagus: a randomized, comparative trial. <i>Gastrointestinal Endoscopy</i> , 2014, 79, 46-54.	1.0	41
280	Impact of pancreatic comorbidities in patients with end-stage liver disease on outcome after liver transplantation. <i>European Journal of Internal Medicine</i> , 2014, 25, 281-285.	2.2	11
281	Analysis of interobserver variability for endomicroscopy of the gastrointestinal tract. <i>Digestive and Liver Disease</i> , 2014, 46, 140-145.	0.9	8
282	Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. <i>Digestive and Liver Disease</i> , 2014, 46, 67-71.	0.9	9
283	Efficacy of SpyGlass™-directed biopsy compared to brush cytology in obtaining adequate tissue for diagnosis in patients with biliary strictures. <i>World Journal of Gastrointestinal Endoscopy</i> , 2014, 6, 137.	1.2	29
284	A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and skin prophylaxis aiming to prevent a skin rash.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20724-e20724.	1.6	0
285	A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3658-TPS3658.	1.6	0
286	Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction. <i>BMC Cancer</i> , 2013, 13, 75.	2.6	9
287	PR3 antibodies do not induce renal pathology in a novel PR3-humanized mouse model for Wegener's granulomatosis. <i>Rheumatology International</i> , 2013, 33, 613-622.	3.0	8
288	Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy. <i>International Journal of Colorectal Disease</i> , 2013, 28, 385-398.	2.2	19

#	ARTICLE	IF	CITATIONS
289	Familial Amyloid Polyneuropathy. <i>Digestive Diseases</i> , 2013, 31, 170-174.	1.9	19
290	Activation of the human immune system via toll-like receptors by the oncolytic parvovirus Hâ€1. <i>International Journal of Cancer</i> , 2013, 132, 2548-2556.	5.1	32
291	Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1667-1672.	2.5	21
292	Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. <i>Hepatology</i> , 2013, 58, 1054-1064.	7.3	138
293	Next generation sequencing of HCC from European and Asian HCC cohorts. Back to p53 and Wnt/ β -catenin. <i>Journal of Hepatology</i> , 2013, 58, 622-624.	3.7	11
294	Facing the dawn of immunotherapy for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 9-10.	3.7	15
295	The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Digestive and Liver Disease</i> , 2013, 45, 408-413.	0.9	31
296	No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: The ATRACTION study, a phase II randomised trial. <i>Digestive and Liver Disease</i> , 2013, 45, 323-329.	0.9	7
297	Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. <i>Transplant International</i> , 2013, 26, 67-74.	1.6	58
298	Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. <i>International Journal of Oncology</i> , 2013, 42, 1297-1304.	3.3	42
299	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Seminars in Liver Disease</i> , 2013, 32, 348-359.	3.6	508
300	Late Consequences of Traumatic Rupture of the Diaphragm. <i>Thoracic and Cardiovascular Surgeon</i> , 2013, 61, 267-269.	1.0	2
301	Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 639-651.	1.6	34
302	Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. <i>Hepatology</i> , 2013, 57, 2358-2368.	7.3	141
303	Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. <i>OncoTargets and Therapy</i> , 2013, 6, 1119.	2.0	16
304	Education in organ donation among students in Germany â€“ results of an intervention study. <i>Annals of Transplantation</i> , 2013, 18, 23-30.	0.9	8
305	Irritable bowel syndrome and organic diseases: A comparative analysis of esophageal motility. <i>World Journal of Gastroenterology</i> , 2013, 19, 6408.	3.3	4
306	Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G498-G506.	3.4	29

#	ARTICLE	IF	CITATIONS
307	CellLineNavigator: a workbench for cancer cell line analysis. <i>Nucleic Acids Research</i> , 2012, 41, D942-D948.	14.5	15
308	Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 718-728.	1.5	38
309	Clinicopathologic Features and Prognosis of Young Patients With Hepatocellular Carcinoma in a Large German Cohort. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 775-778.	2.2	16
310	Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-foot syndrome prophylaxis is performed continuously. <i>Oncology Letters</i> , 2012, 3, 1191-1194.	1.8	7
311	Identification of RARRES1 as a core regulator in liver fibrosis. <i>Journal of Molecular Medicine</i> , 2012, 90, 1439-1447.	3.9	10
312	¹⁸ F-Fluorodeoxyglucose Positron-Emission Tomography (PET) Can Be Used to Assess Inflammation Non-invasively in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2658-2668.	2.3	41
313	Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration. <i>Journal of Hepatology</i> , 2012, 56, 279-281.	3.7	19
314	Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. <i>Journal of Hepatology</i> , 2012, 56, 267-275.	3.7	150
315	Snapshot liver transcriptome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 990-992.	3.7	11
316	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829.	3.7	736
317	Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2012, 54, 93-95.	3.1	53
318	RNA-Seq Atlas—a reference database for gene expression profiling in normal tissue by next-generation sequencing. <i>Bioinformatics</i> , 2012, 28, 1184-1185.	4.1	178
319	LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. <i>BMC Cancer</i> , 2012, 12, 144.	2.6	16
320	Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC. <i>Molecular Cancer</i> , 2012, 11, 55.	19.2	30
321	Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2012, 142, 782-789.e3.	1.3	355
322	Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. <i>Digestive and Liver Disease</i> , 2012, 44, 432-437.	0.9	54
323	Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptor. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 612-620.	1.0	38
324	Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2012, 51, 439-448.	2.7	23

#	ARTICLE	IF	CITATIONS
325	Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1601-1615.	2.3	70
326	The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes. <i>Free Radical Biology and Medicine</i> , 2012, 52, 1911-1917.	2.9	16
327	Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. <i>BMC Cancer</i> , 2012, 12, 109.	2.6	94
328	Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. <i>Journal of Clinical Oncology</i> , 2012, 30, 522-522.	1.6	2
329	Preservation of HUGL-1 expression as a favourable prognostic factor in pancreatic carcinoma. <i>Anticancer Research</i> , 2012, 32, 3153-9.	1.1	8
330	Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. <i>Gut</i> , 2011, 60, 26-33.	12.1	99
331	In Vivo Real Time Imaging of Hepatocyte Apoptosis With Confocal Endomicroscopy Identifies Early Cell Swelling and Barrier Defect. <i>Gastroenterology</i> , 2011, 140, S-926.	1.3	0
332	In Vivo Immunohistochemistry With Labeled Bevacizumab Using Confocal Laser Endomicroscopy in Models of Human Colorectal Cancer. <i>Gastroenterology</i> , 2011, 140, S-10.	1.3	1
333	New imaging techniques and opportunities in endoscopy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 547-553.	17.8	55
334	Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. <i>European Journal of Internal Medicine</i> , 2011, 22, 305-310.	2.2	29
335	Fighting the bushfire in HCC trials. <i>Journal of Hepatology</i> , 2011, 55, 276-277.	3.7	20
336	Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo. <i>Journal of Hepatology</i> , 2011, 55, 1272-1280.	3.7	57
337	In vivo real-time imaging of the liver with confocal endomicroscopy permits visualization of the temporospatial patterns of hepatocyte apoptosis. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G764-G772.	3.4	21
338	Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 213-219.	2.8	92
339	The recipient CYP2D6 allele 4-associated poor metabolizer status correlates with an early fibrosis development after liver transplantation. <i>Transplant International</i> , 2011, 24, 1059-1067.	1.6	3
340	Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1139-1145.	2.5	8
341	Comparative aspects of murine proteinase 3. <i>Rheumatology International</i> , 2011, 31, 1105-1111.	3.0	7
342	VEGF-D Correlates with Metastatic Disease in Gastric Cancer Patients Undergoing Surgery. <i>World Journal of Surgery</i> , 2011, 35, 1010-1016.	1.6	15

#	ARTICLE	IF	CITATIONS
343	Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. <i>BMC Cancer</i> , 2011, 11, 464.	2.6	31
344	The functional cancer map: A systems-level synopsis of genetic deregulation in cancer. <i>BMC Medical Genomics</i> , 2011, 4, 53.	1.5	36
345	IRF4 regulates IL-17A promoter activity and controls ROR γ t-dependent Th17 colitis in vivo. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1343-1358.	1.9	83
346	Liver specific overexpression of platelet-derived growth factor accelerates liver cancer development in chemically induced liver carcinogenesis. <i>International Journal of Cancer</i> , 2011, 128, 1259-1268.	5.1	59
347	Pregnancy in primary sclerosing cholangitis. <i>Gut</i> , 2011, 60, 1117-1121.	12.1	63
348	SNP rs1801157 significantly correlates with distant metastasis in CXCL12 expressing esophagogastric cancer. <i>International Journal of Oncology</i> , 2011, 39, 515-20.	3.3	9
349	AFP Measurement in Monitoring Treatment Response of Advanced Hepatocellular Carcinoma to Sorafenib: Case Report and Review of the Literature. <i>Onkologie</i> , 2011, 34, 538-542.	0.8	4
350	New perspectives on the renal slit diaphragm protein podocin. <i>Modern Pathology</i> , 2011, 24, 1101-1110.	5.5	20
351	Mini-laparoscopy in the endoscopy unit: Safety and outcomes in over one thousand patients. <i>World Journal of Gastrointestinal Endoscopy</i> , 2011, 3, 6.	1.2	14
352	Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. <i>International Journal of Cancer</i> , 2010, 127, 1197-1208.	5.1	27
353	Microarray-Based Gene Expression Analysis of Hepatocellular Carcinoma. <i>Current Genomics</i> , 2010, 11, 261-268.	1.6	30
354	Concurrent Autoimmune Diseases in Patients With Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 208-213.	2.2	181
355	Cetuximab-induced skin exanthema: Improvement by a reactive skin therapy. <i>Molecular Medicine Reports</i> , 2010, 3, 789-93.	2.4	3
356	A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 191-195.	2.3	8
357	K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFR α in colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2010, 25, 181-186.	2.2	21
358	Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. <i>International Journal of Colorectal Disease</i> , 2010, 25, 417-424.	2.2	27
359	Significant Differences Between Crohn's Disease and Ulcerative Colitis Regarding the Impact of Body Mass Index and Initial Disease Activity on Responsiveness to Azathioprine: Results from a European Multicenter Study in 1,176 Patients. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1066-1078.	2.3	37
360	Library of molecular associations: curating the complex molecular basis of liver diseases. <i>BMC Genomics</i> , 2010, 11, 189.	2.8	13

#	ARTICLE	IF	CITATIONS
361	Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. <i>Hepatology</i> , 2010, 51, 1226-1236.	7.3	106
362	Perforin deficiency attenuates inflammation and tumor growth in colitis-associated cancer. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 559-567.	1.9	14
363	Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation. <i>Liver Transplantation</i> , 2010, 16, 109-109.	2.4	41
364	Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: A single-center experience. <i>Liver Transplantation</i> , 2010, 16, 314-323.	2.4	66
365	Collecting evidence for a stem cell hypothesis in HCC. <i>Gut</i> , 2010, 59, 870-871.	12.1	10
366	Interleukin 6 (IL-6) Deficiency Delays Lupus Nephritis in MRL- <i>Fas</i> ^{lpr} Mice: The IL-6 Pathway as a New Therapeutic Target in Treatment of Autoimmune Kidney Disease in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 60-70.	2.0	135
367	Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy. <i>Gut</i> , 2010, 59, 1046-1055.	12.1	110
368	$\hat{N}p73\hat{P}$ is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. <i>Cell Cycle</i> , 2010, 9, 2629-2639.	2.6	25
369	Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment. <i>Oncology</i> , 2010, 79, 85-92.	1.9	35
370	Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study. <i>Onkologie</i> , 2010, 33, 684-690.	0.8	3
371	S1526: Endoflag: A New Software Based Filter Technology Significantly Increases the Diagnostic Yield of Colorectal Neoplasia During Screening Colonoscopy. A Prospective Randomized Controlled Trial. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB185.	1.0	1
372	S1586: I-Scan Is As Effective As Acetic Acid Guided Chromoendoscopy and Superior to Random Biopsies Diagnosing Barrett's Epithelium - A Prospective Randomized Trial. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB201.	1.0	1
373	S1619: Chromoscopic Guided Endomicroscopy - A New Atraumatic Surveillance Option for Patients With Ureterosigmoidostomy or Rectosigmoid Pouch. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB209.	1.0	0
374	T1584: High Incidence of Ectopic Varices in Liver Transplant Candidates. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB315.	1.0	0
375	T1620: Endomicroscopy Is Able to Identify Superficial but Not Deep Intestinal Metaplasia of the Gastric Mucosa. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB324.	1.0	1
376	W1500: High Definition Plus Endoscopy in Conjunction With Pan-Chromoendoscopy Does Not Lead to an Increased Yield for Intraepithelial Neoplasia in Patients With Long Lasting Crohn's Disease. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB343-AB344.	1.0	0
377	W1529: Confocal Endomicroscopy for the Diagnosis of Ultra-Structural Changes in Non-Erosive Reflux Disease (NERD). <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB351.	1.0	1
378	Future perspectives in hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2010, 42, S302-S309.	0.9	62

#	ARTICLE	IF	CITATIONS
379	In Vivo Molecular Imaging of Colorectal Cancer With Confocal Endomicroscopy by Targeting Epidermal Growth Factor Receptor. <i>Gastroenterology</i> , 2010, 138, 435-446.	1.3	201
380	Near-infrared confocal imaging during mini-laparoscopy: A novel rigid endomicroscope with increased imaging plane depth. <i>Journal of Hepatology</i> , 2010, 53, 84-90.	3.7	60
381	Liver-specific Ldb1 deletion results in enhanced liver cancer development. <i>Journal of Hepatology</i> , 2010, 53, 1078-1084.	3.7	16
382	Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). <i>European Journal of Internal Medicine</i> , 2010, 21, 208-215.	2.2	25
383	Novel inhibitors in development for hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 615-629.	4.1	30
384	Contrast-Enhanced Ultrasonography With SonoVue. <i>Journal of Ultrasound in Medicine</i> , 2009, 28, 421-434.	1.7	49
385	High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. <i>World Journal of Gastroenterology</i> , 2009, 15, 2089.	3.3	185
386	IFN- γ -Induced Apoptosis in Hepatocellular Carcinoma Involves Promyelocytic Leukemia Protein and TRAIL Independently of p53. <i>Cancer Research</i> , 2009, 69, 855-862.	0.9	73
387	Systemic Therapies in Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2009, 27, 175-188.	1.9	58
388	Downregulation of α -galactosidase A upregulates CD77: functional impact for Fabry nephropathy. <i>Kidney International</i> , 2009, 75, 399-407.	5.2	22
389	Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. <i>Hepatology</i> , 2009, 49, 627-636.	7.3	130
390	EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes. <i>International Journal of Cancer</i> , 2009, 124, 120-129.	5.1	24
391	Immunoabsorption with tryptophan columns: A therapeutic option for the treatment of rheumatoid arthritis with septic complications. <i>Journal of Clinical Apheresis</i> , 2009, 24, 37-41.	1.3	2
392	IRF4 selectively controls cytokine gene expression in chronic intestinal inflammation. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2009, 57, 369-376.	2.3	17
393	A systems biology perspective on cholangiocellular carcinoma development: Focus on MAPK-signaling and the extracellular environment. <i>Journal of Hepatology</i> , 2009, 50, 1122-1131.	3.7	18
394	Show me your signaling and I tell you who you are. <i>Journal of Hepatology</i> , 2009, 51, 638-639.	3.7	2
395	Coexistence of Cullen's and Grey Turner's Signs in Acute Pancreatitis. <i>American Journal of Medicine</i> , 2009, 122, 333-334.	1.5	16
396	GERD: High Definition Endoscopy (HD+) in Conjunction with I-Scan and Chromoendoscopy Reliably Identifies Minimal Change Esophagitis in NERD and Asymptomatic Patients. <i>Gastrointestinal Endoscopy</i> , 2009, 69, AB344.	1.0	1

#	ARTICLE	IF	CITATIONS
397	In Vivo Molecular Imaging of VEGF in Gastrointestinal Cancer Using Confocal Laser Endomicroscopy. <i>Gastrointestinal Endoscopy</i> , 2009, 69, AB130.	1.0	2
398	Confocal Laser Endomicroscopy for the In Vivo Identification, Localization and Quantification of Tissue Based Bacteria in Patients with Different Types of Colitis. <i>Gastrointestinal Endoscopy</i> , 2009, 69, AB131.	1.0	4
399	High Definition Plus Colonoscopy Combined with I-Scan Is Superior in the Detection and Characterization of Colorectal Neoplasias Compared to Standard Video Colonoscopy - A Prospective Randomized Trial. <i>Gastrointestinal Endoscopy</i> , 2009, 69, AB131-AB132.	1.0	4
400	Simultaneous confocal laser endomicroscopy and chromoendoscopy with topical cresyl violet. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 959-968.	1.0	80
401	Small Bowel Enteroscopy: Feasibility and Safety of the New Balloon Guided Endoscopy System Using Different High Definition, Confocal and Standard Endoscopes. <i>Gastrointestinal Endoscopy</i> , 2009, 69, AB364.	1.0	3
402	Near Infrared Confocal Imaging of the Human Liver During Ongoing Mini-Laparoscopy: A Newly Developed Rigid Endomicroscope with Increased Imaging Plane Depth. <i>Gastrointestinal Endoscopy</i> , 2009, 69, AB373.	1.0	0
403	Characteristics and Long-term Prognosis of the Autoimmune Hepatitis/Primary Sclerosing Cholangitis Overlap Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 75-80.	2.2	77
404	Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 489-495.	2.2	146
405	Update on autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2009, 15, 1035.	3.3	28
406	Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2009, 15, 449.	3.3	34
407	Hepatocellular carcinoma in patients with autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , 2009, 15, 578.	3.3	64
408	TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. <i>World Journal of Gastroenterology</i> , 2009, 15, 5924.	3.3	33
409	Treatment of Crohn's Disease with Leflunomide as Second-Line Immunosuppression. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1025-1032.	2.3	16
410	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 169-176.	7.3	1,553
411	All-trans retinoic acid for treatment of chronic hepatitis C. <i>Liver International</i> , 2008, 28, 347-354.	3.9	27
412	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	27.0	12,004
413	High Definition Endoscopy (HD+) with I-Scan and Lugol's Solution for the Detection of Inflammation and Neoplasia in Patients with GERD. <i>Gastrointestinal Endoscopy</i> , 2008, 67, AB98.	1.0	1
414	Staging of Colorectal Neoplasia with Confocal Laser Endomicroscopy Using Two Contrast Agents Simultaneously. <i>Gastrointestinal Endoscopy</i> , 2008, 67, AB123.	1.0	5

#	ARTICLE	IF	CITATIONS
415	High Definition Colonoscopy (HD+) with I-Scan Function Allows to Recognize and Characterize Flat Neoplastic Changes As Precisely As Chromoendoscopy. <i>Gastrointestinal Endoscopy</i> , 2008, 67, AB125.	1.0	8
416	Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?. <i>American Journal of Gastroenterology</i> , 2008, 103, 3063-3070.	0.4	179
417	In vivo confocal laser laparoscopy allows real time subsurface microscopy in animal models of liver disease. <i>Journal of Hepatology</i> , 2008, 48, 91-97.	3.7	31
418	Sorafenib in advanced hepatocellular carcinoma â€œ We have won a battle not the war. <i>Journal of Hepatology</i> , 2008, 49, 871-873.	3.7	33
419	Human leukocyte elastase counteracts matrix metalloproteinase-7 induced apoptosis resistance of tumor cells. <i>Cancer Letters</i> , 2008, 268, 331-339.	7.2	5
420	Cloning and characterization of the promoter of Hugl-2, the human homologue of <i>Drosophila</i> lethal giant larvae (lgl) polarity gene. <i>Biochemical and Biophysical Research Communications</i> , 2008, 366, 1067-1073.	2.1	14
421	Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. <i>Gene</i> , 2008, 423, 23-28.	2.2	52
422	The transcription factor NFATc2 controls IL-6â€œdependent T cell activation in experimental colitis. <i>Journal of Experimental Medicine</i> , 2008, 205, 2099-2110.	8.5	99
423	Cutting Edge: A Key Pathogenic Role of IL-27 in T Cell- Mediated Hepatitis. <i>Journal of Immunology</i> , 2008, 180, 30-33.	0.8	38
424	Transforming Growth Factor-Î²â€œMediated Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Expression and Apoptosis in Hepatoma Cells Requires Functional Cooperation between Smad Proteins and Activator Protein-1. <i>Molecular Cancer Research</i> , 2008, 6, 1169-1177.	3.4	22
425	Incidence of HAV and HBV Infections and Vaccination Rates in Patients With Autoimmune Liver Diseases. <i>American Journal of Gastroenterology</i> , 2008, 103, 138-146.	0.4	50
426	Serologic Markers Compared With Liver Biopsy for Monitoring Disease Activity in Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 926-930.	2.2	135
427	Strong Expression of Chemokine Receptor<i>CXCR</i>4 by Renal Cell Carcinoma Correlates with Advanced Disease. <i>Journal of Oncology</i> , 2008, 2008, 1-6.	1.3	31
428	Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas. <i>Clinical Medicine Oncology</i> , 2008, 2, CMO.S919.	0.3	1
429	The transcription factor IFN regulatory factorâ€œ4 controls experimental colitis in mice via T cellâ€œderived IL-6. <i>Journal of Clinical Investigation</i> , 2008, 118, 2415-26.	8.2	94
430	Multidisciplinary management of gastric and gastroesophageal cancers. <i>World Journal of Gastroenterology</i> , 2008, 14, 3773.	3.3	40
431	Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein. <i>World Journal of Gastroenterology</i> , 2008, 14, 3819.	3.3	16
432	Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. <i>World Journal of Gastroenterology</i> , 2008, 14, 3829.	3.3	36

#	ARTICLE	IF	CITATIONS
433	VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. <i>World Journal of Gastroenterology</i> , 2008, 14, 4156.	3.3	36
434	Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. <i>World Journal of Gastroenterology</i> , 2008, 14, 4721.	3.3	44
435	Technology Insight: confocal laser endoscopy for in vivo diagnosis of colorectal cancer. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 480-490.	4.3	103
436	Regulation of B cell homeostasis and activation by the tumor suppressor gene <i>CYLD</i> . <i>Journal of Experimental Medicine</i> , 2007, 204, 2615-2627.	8.5	91
437	The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. <i>Gut</i> , 2007, 56, 1572-1578.	12.1	72
438	Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. <i>International Immunology</i> , 2007, 19, 685-693.	4.0	54
439	Cutting Edge: <i>Trans</i> Signaling via the Soluble IL-6R Abrogates the Induction of FoxP3 in Naive CD4+CD25 ^{hi} T Cells. <i>Journal of Immunology</i> , 2007, 179, 2041-2045.	0.8	209
440	Targeting of the Transcription Factor STAT4 by Antisense Phosphorothioate Oligonucleotides Suppresses Collagen-Induced Arthritis. <i>Journal of Immunology</i> , 2007, 178, 3427-3436.	0.8	57
441	Prospective Randomized Comparison of Minilaparoscopy and Percutaneous Liver Biopsy. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 103-110.	2.2	87
442	Genome-wide analysis of factors regulating gene expression in liver. <i>Gene</i> , 2007, 389, 114-121.	2.2	6
443	IL-28A Is a Key Regulator of T-Cell-Mediated Liver Injury via the T-Box Transcription Factor T-Bet. <i>Gastroenterology</i> , 2007, 132, 358-371.	1.3	39
444	Chromoscopy-Guided Endomicroscopy Increases the Diagnostic Yield of Intraepithelial Neoplasia in Ulcerative Colitis. <i>Gastroenterology</i> , 2007, 132, 874-882.	1.3	518
445	Endoscopic Surveillance in Ulcerative Colitis: Smart Biopsies Do It Better. <i>Gastroenterology</i> , 2007, 133, 742-745.	1.3	18
446	80 mg Esomeprazole Daily Over 6 Months Does Not Lead to a Significant Regression of Barrett's Esophagus - Results from a Prospective Randomized Trial. <i>Gastrointestinal Endoscopy</i> , 2007, 65, AB151.	1.0	1
447	Methylene Blue Aided Cholangioscopy in Patients with Biliary Strictures-A Novel Method to Detect GI Malignancies. <i>Gastrointestinal Endoscopy</i> , 2007, 65, AB211.	1.0	0
448	Endomicroscopy in Comparison with Acetic Acid Guided Endoscopy for the Detection of Barrett's Esophagus-A Prospective Randomized Cross Over Trial. <i>Gastrointestinal Endoscopy</i> , 2007, 65, AB352.	1.0	0
449	Interobserver Variation and Standardized Training for Confocal Laser Endomicroscopy Image Interpretation in the Upper and Lower GI Tract. <i>Gastrointestinal Endoscopy</i> , 2007, 65, AB354.	1.0	7
450	Methylene blue-aided cholangioscopy unravels the endoscopic features of ischemic-type biliary lesions after liver transplantation. <i>Gastrointestinal Endoscopy</i> , 2007, 66, 1052-1058.	1.0	26

#	ARTICLE	IF	CITATIONS
451	Exacerbation of ulcerative colitis after rituximab salvage therapy. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1365-1368.	1.9	236
452	Lung CD11c ⁺ cells from mice deficient in Epstein-Barr virus-induced gene 3 (EBI3) prevent airway hyperresponsiveness in experimental asthma. <i>European Journal of Immunology</i> , 2007, 37, 1663-1677.	2.9	11
453	IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. <i>European Journal of Immunology</i> , 2007, 37, 1809-1816.	2.9	173
454	Efficacy of an escalating dose regimen of pegylated interferon α 2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. <i>Transplant International</i> , 2007, 20, 583-590.	1.6	39
455	Hepatitis viruses: live and let die. <i>Liver International</i> , 2007, 27, 293-301.	3.9	47
456	Enhanced Sensitivity to CD95-Induced Apoptosis in ob/ob Mice. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2396-2402.	2.3	12
457	<i>In vivo</i> subsurface morphological and functional cellular and subcellular imaging of the gastrointestinal tract with confocal mini-microscopy. <i>World Journal of Gastroenterology</i> , 2007, 13, 2160.	3.3	29
458	Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?. <i>World Journal of Gastroenterology</i> , 2007, 13, 3605.	3.3	32
459	In Vivo Histology of Barrett's Esophagus and Associated Neoplasia by Confocal Laser Endomicroscopy. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 979-987.	4.4	470
460	Microscopic Changes in Non Erosive Reflux Disease (NERD) Can Be Diagnosed During Ongoing Endoscopy By Confocal Laser Endomicroscopy (CLE). <i>Gastrointestinal Endoscopy</i> , 2006, 63, AB243.	1.0	5
461	Methylene Blue Aided Cholangioscopy for the Detection of Neoplastic Biliary Lesions. <i>Gastrointestinal Endoscopy</i> , 2006, 63, AB288.	1.0	1
462	The role of apoptosis versus oncotic necrosis in liver injury: Facts or faith?. <i>Journal of Hepatology</i> , 2006, 44, 984-993.	3.7	31
463	Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. <i>Journal of Hepatology</i> , 2006, 45, 419-428.	3.7	209
464	Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. <i>World Journal of Gastroenterology</i> , 2006, 12, 5513.	3.3	23
465	Das Interdisziplinäre Hepatologische Zentrum Mainz. <i>Visceral Medicine</i> , 2006, 22, 219-223.	1.3	1
466	Actin binding LIM protein 3 (abLIM3). <i>International Journal of Molecular Medicine</i> , 2006, 17, 129.	4.0	10
467	Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. <i>Oncology Reports</i> , 2006, 16, 1159.	2.6	19
468	Overexpression of STAT-1 by adenoviral gene transfer does not inhibit hepatitis B virus replication. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 167-174.	1.6	3

#	ARTICLE	IF	CITATIONS
469	In vivo molecular and morphological imaging by real time confocal mini-microscopy. , 2006, , .		0
470	Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. International Journal of Oncology, 2006, 28, 25.	3.3	40
471	Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. International Journal of Oncology, 2006, 29, 973.	3.3	20
472	Alloimmune hemolytic anemia after liver transplantation from an ABO-identical and Rh-nonidentical donor in a patient with postpartum Budd-Chiari syndrome. Transplant International, 2006, 19, 514-515.	1.6	2
473	Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver International, 2006, 26, 319-325.	3.9	27
474	Apoptosis in liver disease. Liver International, 2006, 26, 904-911.	3.9	106
475	Long-Term Effectiveness of Azathioprine in IBD Beyond 4 Years: A European Multicenter Study in 1176 Patients. Digestive Diseases and Sciences, 2006, 51, 1516-1524.	2.3	82
476	Crohnâ€™s-like Colitis in a Patient with Immunodeficiency Associated with a Defect in Expression of Inducible Costimulator. Digestive Diseases and Sciences, 2006, 51, 711-717.	2.3	9
477	Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer, 2006, 6, 190.	2.6	29
478	Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer, 2006, 6, 232.	2.6	92
479	Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. BMC Cancer, 2006, 6, 290.	2.6	50
480	Hepatitis C virus re-infection: new perspectives. Clinical Transplantation, 2006, 20, 117-123.	1.6	1
481	Current bioinformatics tools in genomic biomedical research (Review). International Journal of Molecular Medicine, 2006, 17, 967.	4.0	12
482	Azathioprine Suppresses Ezrin-Radixin-Moesin-Dependent T Cell-APC Conjugation through Inhibition of Vav Guanosine Exchange Activity on Rac Proteins. Journal of Immunology, 2006, 176, 640-651.	0.8	182
483	Cutting Edge: IL-23 Cross-Regulates IL-12 Production in T Cell-Dependent Experimental Colitis. Journal of Immunology, 2006, 177, 2760-2764.	0.8	224
484	Pregnancy in Autoimmune Hepatitis: Outcome and Risk Factors. American Journal of Gastroenterology, 2006, 101, 556-560.	0.4	200
485	Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. Journal of Experimental Medicine, 2006, 203, 1875-1881.	8.5	162
486	Evaluation of F-Actin ELISA for the Diagnosis of Autoimmune Hepatitis. American Journal of Gastroenterology, 2006, 101, 2731-2736.	0.4	82

#	ARTICLE	IF	CITATIONS
487	Nitric Oxide Promotes Resistance to Tumor Suppression by CTLs. <i>Journal of Immunology</i> , 2006, 176, 3923-3930.	0.8	3
488	Characterization of human gene encoding SLA/LP autoantigen and its conserved homologs in mouse, fish, fly, and worm. <i>World Journal of Gastroenterology</i> , 2006, 12, 902.	3.3	6
489	In silico characterization of LZTS3, a potential tumor suppressor. <i>Oncology Reports</i> , 2005, 14, 547.	2.6	5
490	Hepatic over-expression of TGF-beta1 promotes LPS-induced inflammatory cytokine secretion by liver cells and endotoxemic shock. <i>Immunology Letters</i> , 2005, 101, 217-222.	2.5	27
491	Activation Pattern of Signal Transducers and Activators of Transcription (STAT) Factors in Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2005, 100, 64-72.	0.4	205
492	Reduced expression of Hupl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer. <i>Oncogene</i> , 2005, 24, 3100-3109.	5.9	128
493	MORT1/FADD is involved in liver regeneration. <i>World Journal of Gastroenterology</i> , 2005, 11, 7248.	3.3	13
494	Asthmatic changes in mice lacking T-bet are mediated by IL-13. <i>International Immunology</i> , 2005, 17, 993-1007.	4.0	77
495	The p53 Tumor Suppressor Network Is a Key Responder to Microenvironmental Components of Chronic Inflammatory Stress. <i>Cancer Research</i> , 2005, 65, 10255-10264.	0.9	93
496	EBV-Induced Gene 3 Transcription Is Induced by TLR Signaling in Primary Dendritic Cells via NF- κ B Activation. <i>Journal of Immunology</i> , 2005, 174, 2814-2824.	0.8	139
497	Hepatitis C Virus Core Protein Inhibits Tumor Suppressor Protein Promyelocytic Leukemia Function in Human Hepatoma Cells. <i>Cancer Research</i> , 2005, 65, 10830-10837.	0.9	53
498	A Genetic Basis for IFN- γ Production and T-bet Expression in Humans. <i>Journal of Immunology</i> , 2005, 175, 5457-5462.	0.8	30
499	Apoptosis and age-dependant induction of nuclear and mitochondrial etheno-DNA adducts in Long-Evans Cinnamon (LEC) rats: enhanced DNA damage by dietary curcumin upon copper accumulation. <i>Carcinogenesis</i> , 2005, 26, 1307-1315.	2.8	84
500	Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 1743-1750.	7.0	233
501	Characterization of OEFT, a LIM protein. <i>International Journal of Molecular Medicine</i> , 2005, 15, 513.	4.0	1
502	In silico characterization of an Iroquois family-related homeodomain protein. <i>International Journal of Molecular Medicine</i> , 2005, 16, 443.	4.0	0
503	LASS6, an additional member of the longevity assurance gene family. <i>International Journal of Molecular Medicine</i> , 2005, 16, 905.	4.0	5
504	Colorectal cancer. <i>Lancet, The</i> , 2005, 365, 153-165.	13.7	1,030

#	ARTICLE	IF	CITATIONS
505	6-Thioguanosine Diphosphate and Triphosphate Levels in Red Blood Cells and Response to Azathioprine Therapy in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1007-1014.	4.4	81
506	Diagnosing <i>Helicobacter pylori</i> In Vivo by Confocal Laser Endoscopy. <i>Gastroenterology</i> , 2005, 128, 2119-2123.	1.3	165
507	The IL-6R chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. <i>Journal of Clinical Investigation</i> , 2005, 115, 313-325.	8.2	292
508	TGF β regulates the CD4+CD25+ T-cell pool and the expression of Foxp3 in vivo. <i>International Immunology</i> , 2004, 16, 1241-1249.	4.0	98
509	(Neo)adjuvant Strategies of Advanced Gastric Carcinoma: Time for a Change?. <i>Digestive Diseases</i> , 2004, 22, 345-350.	1.9	18
510	Chromoendoscopy and Magnifying Endoscopy in Patients with Gastroesophageal Reflux Disease. <i>Digestive Diseases</i> , 2004, 22, 142-147.	1.9	25
511	Cutting Edge: TGF- β 2 Signaling Is Required for the In Vivo Expansion and Immunosuppressive Capacity of Regulatory CD4+CD25+ T Cells. <i>Journal of Immunology</i> , 2004, 173, 6526-6531.	0.8	376
512	A Critical Regulatory Role of Leucine Zipper Transcription Factor c-Maf in Th1-Mediated Experimental Colitis. <i>Journal of Immunology</i> , 2004, 173, 3446-3455.	0.8	11
513	Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. <i>Oncogene</i> , 2004, 23, 3732-3736.	5.9	119
514	The human protein Hugi-1 substitutes for <i>Drosophila</i> Lethal giant larvae tumour suppressor function in vivo. <i>Oncogene</i> , 2004, 23, 8688-8694.	5.9	112
515	Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. <i>BMC Cancer</i> , 2004, 4, 38.	2.6	26
516	Current concept of pathophysiological understanding and natural course of ulcerative colitis. <i>Langenbeck's Archives of Surgery</i> , 2004, 389, 341-349.	1.9	20
517	A stage-specific functional role of the leucine zipper transcription factor c-Maf in lung Th2 cell differentiation. <i>European Journal of Immunology</i> , 2004, 34, 3401-3412.	2.9	11
518	HSP60 and CpG-DNA-oligonucleotides differentially regulate LPS-tolerance of hepatic Kupffer cells. <i>Immunology Letters</i> , 2004, 93, 199-204.	2.5	28
519	Cutting Edge: TGF- β 2 Induces a Regulatory Phenotype in CD4+CD25+ T Cells through Foxp3 Induction and Down-Regulation of Smad7. <i>Journal of Immunology</i> , 2004, 172, 5149-5153.	0.8	1,060
520	Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome. <i>Gastroenterology</i> , 2004, 126, 849-858.	1.3	52
521	Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. <i>Gastroenterology</i> , 2004, 127, 706-713.	1.3	823
522	Susceptibility to collagen-induced arthritis is modulated by TGF β responsiveness of T cells. <i>Arthritis Research</i> , 2004, 6, R114.	2.0	40

#	ARTICLE	IF	CITATIONS
523	TGF- β 2 Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling. <i>Immunity</i> , 2004, 21, 491-501.	14.3	700
524	Sensitizing to apoptosisâ€”sharpening the medical sword. <i>Journal of Hepatology</i> , 2004, 40, 335-336.	3.7	25
525	Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure. <i>Journal of Hepatology</i> , 2004, 41, 67-74.	3.7	46
526	Subsurface Analysis of Colon Neoplasias by Confocal Laser Colonoscopy and Virtual Histology: A Novel Diagnostic Tool for Predicting Cancer During Screening Colonoscopy. <i>Gastrointestinal Endoscopy</i> , 2004, 59, P97.	1.0	0
527	In vivo Fluorescence Confocal Laser Colonoscopy for Prediction of Neoplasia in Patients with Ulcerative Colitis. <i>Gastrointestinal Endoscopy</i> , 2004, 59, P97.	1.0	9
528	Safety and Efficacy of Methylene Blue-Aided Chromoendoscopy in Ulcerative Colitis: A Prospective Pilot Study Upon Previous Chromoendoscopies. <i>Gastrointestinal Endoscopy</i> , 2004, 59, P97.	1.0	9
529	Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. <i>Journal of General Virology</i> , 2004, 85, 2829-2836.	2.9	42
530	Dominant negative MORT1/FADD rescues mice from CD95 and TNF-induced liver failure. <i>Hepatology</i> , 2003, 37, 129-135.	7.3	25
531	A key pathogenic role for the STAT1/T-bet signaling pathway in T-cell-mediated liver inflammation. <i>Hepatology</i> , 2003, 38, 1573-1580.	7.3	35
532	Tumor necrosis factor-receptor 2 (TNF-R2, p80) is the principal mediator of TNF in the pathogenesis of experimental colitis. <i>Gastroenterology</i> , 2003, 124, A319.	1.3	0
533	Increased sensitivity of fatty liver against Cd95 induced apoptosis in leptin deficient Ob/Ob mice. <i>Gastroenterology</i> , 2003, 124, A758.	1.3	0
534	Retreatment with pegylated interferon-alpha2b plus ribavirin in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin. <i>Gastroenterology</i> , 2003, 124, A768.	1.3	4
535	A dichotomous regulatory role for C-maf in T cell dependent experimental colitis. <i>Gastroenterology</i> , 2003, 124, A320.	1.3	0
536	A novel molecular mechanism of action for azathioprine in IBD: 6-Thio-GTP induces apoptosis of lamina propria T cells via blockade of the GTPase Rac1. <i>Gastroenterology</i> , 2003, 124, A321.	1.3	0
537	High constitutive IL-12 p40 promoter activity in the terminal ileum on healthy mice mediated by lamina propria dendritic cells. <i>Gastroenterology</i> , 2003, 124, A105.	1.3	0
538	Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. <i>Gastroenterology</i> , 2003, 124, 880-888.	1.3	865
539	A key pathogenic role for the stat1-T-bet signaling pathway in con a-induced liver injury. <i>Gastroenterology</i> , 2003, 124, A719.	1.3	0
540	Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. <i>American Journal of Gastroenterology</i> , 2003, 98, 504-505.	0.4	38

#	ARTICLE	IF	CITATIONS
541	Hepatic disseminated tumor cells in colorectal cancer UICC stage 4 patients: Prognostic implications. <i>International Journal of Oncology</i> , 2003, 23, 791.	3.3	6
542	Comparison of a 48-Hour Infusion of 5-Fluorouracil without Folinic Acid with 24-Hour Folinic Acid/5-Fluorouracil in Patients with Metastatic Colorectal Cancer Refractory to Bolus Folinic Acid/5-Fluorouracil. <i>Chemotherapy</i> , 2003, 49, 85-89.	1.6	8
543	Impairment of TGF- β signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G525-G535.	3.4	49
544	Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. <i>Journal of Clinical Investigation</i> , 2003, 112, 693-706.	8.2	295
545	Different Efficiency of Heat Shock Proteins (HSP) to Activate Human Monocytes and Dendritic Cells: Superiority of HSP60. <i>Journal of Immunology</i> , 2002, 169, 6141-6148.	0.8	157
546	Treatment of T Cell-Dependent Experimental Colitis in SCID Mice by Local Administration of an Adenovirus Expressing IL-18 Antisense mRNA. <i>Journal of Immunology</i> , 2002, 168, 411-420.	0.8	123
547	A New Model of Chronic Colitis in SCID Mice Induced by Adoptive Transfer of CD62L+ CD4+ T Cells: Insights into the Regulatory Role of Interleukin-6 on Apoptosis. <i>Pathobiology</i> , 2002, 70, 170-176.	3.8	55
548	Dead or alive – NF- κ B, the guardian which tips the balance. <i>Journal of Hepatology</i> , 2002, 36, 827-828.	3.7	6
549	Individual immune response to hepatitis A and B vaccine is mostly genetically determined. <i>Journal of Hepatology</i> , 2002, 36, 23-24.	3.7	0
550	The role of TGF-beta in liver regeneration: studies with CRP/TGF-beta transgenic mice. <i>Journal of Hepatology</i> , 2002, 36, 79.	3.7	0
551	Immunomodulation with interleukin-12 improves the efficacy of therapeutic vaccine in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2002, 36, 224.	3.7	0
552	Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo. <i>European Journal of Immunology</i> , 2002, 32, 3142-3151.	2.9	75
553	Duration of immunosuppressive therapy in autoimmune hepatitis. <i>Journal of Hepatology</i> , 2001, 34, 354-355.	3.7	112
554	Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 279-286.	2.9	56
555	Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. <i>Trends in Immunology</i> , 2001, 22, 21-26.	6.8	170
556	Immunotherapeutic approaches to inflammatory bowel diseases. <i>Expert Opinion on Biological Therapy</i> , 2001, 1, 455-466.	3.1	11
557	Apoptosis in liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 785-790.	1.6	57
558	Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. <i>European Journal of Immunology</i> , 2001, 31, 2071-2079.	2.9	45

#	ARTICLE	IF	CITATIONS
559	Treatment of Allergic Airway Inflammation and Hyperresponsiveness by Antisense-Induced Local Blockade of Gata-3 Expression. <i>Journal of Experimental Medicine</i> , 2001, 193, 1247-1260.	8.5	238
560	Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. <i>Cancer Gene Therapy</i> , 2001, 8, 158-167.	4.6	68
561	Hepatocellular expression of a dominant-negative mutant TGF- β 2 type II receptor accelerates chemically induced hepatocarcinogenesis. <i>Oncogene</i> , 2001, 20, 5015-5024.	5.9	68
562	Regulation of IL-12 p40 Promoter Activity in Primary Human Monocytes: Roles of NF- κ B, CCAAT/Enhancer-Binding Protein β , and PU.1 and Identification of a Novel Repressor Element (GA-12) That Responds to IL-4 and Prostaglandin E2. <i>Journal of Immunology</i> , 2001, 167, 2608-2618.	0.8	84
563	Expression of stress protein gp96, a tumor rejection antigen, in human colorectal cancer. , 2000, 86, 489-493.		25
564	Heterozygosity for the hemochromatosis gene in liver diseases - prevalence and effects on liver histology. <i>Liver International</i> , 2000, 20, 482-486.	3.9	37
565	Apoptosis and the liver. <i>Seminars in Cancer Biology</i> , 2000, 10, 173-184.	9.6	137
566	Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients?. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 644-649.	0.7	35
567	Rapid development of Epstein-Barr virus-associated Hodgkin's disease after cessation of foscarnet therapy in an HIV-infected patient. <i>International Journal of STD and AIDS</i> , 2000, 11, 609-610.	1.1	3
568	IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-6. <i>Journal of Immunology</i> , 2000, 164, 4672-4677.	0.8	98
569	FDG-PET: A novel non-invasive method to detect affected bowel segments in Crohn's disease?. <i>Gastroenterology</i> , 2000, 118, A320.	1.3	2
570	A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct is associated with increased TNF- α production and antineutrophil cytoplasmic autoantibodies (ANCA). <i>Gastroenterology</i> , 2000, 118, A1014.	1.3	0
571	Downregulation of the TH2 T cell associated transcription factors GATA-3 and NFA Tc1/2 in lamina propria T lymphocytes in Crohn's disease. <i>Gastroenterology</i> , 2000, 118, A663.	1.3	1
572	Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of T cell resistance against apoptosis. <i>Gastroenterology</i> , 2000, 118, A863.	1.3	6
573	Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. <i>Gastroenterology</i> , 2000, 119, 1663-1671.	1.3	115
574	Lack of TNF receptor down-regulation on lamina propria macrophages and T-cells despite increased TNF α levels in Crohn's disease. <i>Gastroenterology</i> , 2000, 118, A1125.	1.3	1
575	Severe hepatic injury in interleukin-18 transgenic mice. <i>Gastroenterology</i> , 2000, 118, A188.	1.3	0
576	A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct is associated with increased TNF- α production and autoantibodies. <i>Journal of Hepatology</i> , 2000, 33, 862-872.	3.7	35

#	ARTICLE	IF	CITATIONS
577	Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. <i>Journal of Hepatology</i> , 1999, 31, 635-640.	3.7	142
578	p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs. <i>Journal of Experimental Medicine</i> , 1998, 188, 2033-2045.	8.5	788
579	CD95-Induced Apoptosis in Human Liver Disease. <i>Seminars in Liver Disease</i> , 1998, 18, 141-151.	3.6	115
580	Apoptosis in liver disease. <i>Journal of Hepatology</i> , 1997, 27, 405-412.	3.7	98
581	Serum antibodies against <i>Helicobacter pylori</i> proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma. <i>Digestive Diseases and Sciences</i> , 1997, 42, 1652-1659.	2.3	119
582	In vitro experimental infection of primary human hepatocytes with hepatitis B virus. <i>Gastroenterology</i> , 1994, 106, 664-673.	1.3	124
583	Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer. <i>Oncology Reports</i> , 0, , .	2.6	14